Issue link: https://www.e-digitaleditions.com/i/1463386
Inhalation April 2022 33 Pre-formulation and formulation capabilities Catalent Inhalation has the capabilities, expertise and state-of-the-art facilities to expedite product development, from concept and feasibility studies through commercial manufacture and release testing. Whether a single service or a comprehensive develop- ment package is required, Catalent offers end-to-end inhalation expertise across dry powder inhaler (DPI) and unit and bi-dose nasal spray dose forms. Catalent also provides integrated analytical, particle size engi- neering and clinical trial supply services. Catalent US: + 1 888 SOLUTION (765-8846) www.catalent.com Developing biologics for respiratory delivery Inhaled and nasal delivery of biologic or DNA-based modalities for both respiratory and systemic targets presents unique challenges for effective product devel- opment. Intertek will present the workshop, "Devel- oping biologics for respiratory delivery," on May 3 at RDD 2022. e workshop will address key princi- ples, challenges and technologies involved in build- ing effective OINDPs from a range of biologic active pharmaceutical ingredients (APIs). It will also draw examples from real-world projects to highlight key parts of development programs and decision-making/ development processes. Intertek Melbourn UK: +44 1763 261648 bd.melbourn@intertek.com www.intertek.com Plasma process for treating MDI canisters H&T Presspart offers a unique plasma process—man- ufactured under license from Portal Medical Ltd—for treating the internal surfaces of metered dose inhaler (MDI) canisters, which can help ensure the active drug content does not stick to the canister wall. is fluorocarbon polymerization (FCP) plasma treatment process can improve the surface energy performance of an MDI canister, which can enhance drug stability in formulations where interactions with the alumin- ium substrate can lead to product degradation and reduced shelf life. H&T Presspart UK: +44 1254 582233 Blackburn@presspart.com www.presspart.com Inhaled and nasal drug delivery systems RxPack is a global leader in pharmaceutical dispens- ing solutions and inhaled and nasal drug delivery sys- tems. Specializing in pMDIs, it offers valves suitable for solution and suspension formulations, single- and double-stage filling and combination or single for- mulations. Low moisture ingress and fast filling are among key features. Valves and actuators are avail- able for HFA 134a and green gasses. RxPack can also guide customers from R&D to full-scale manufac- turing. For pMDI filling equipment, RxPack works in partnership with Coster, which manufactures lab- scale machines and high-speed lines. RxPack S.r.l. Italy: +39 0341 18960 info@rxpack.it www.rxpack.eu